Zenagamtide sodium

泽那加肽钠 · Peptide Drug Intermediates · CAS 3005889-81-3

CAS Number
3005889-81-3
Molecular Formula
C343H550N94O116·Na
Molecular Weight
7869.57
Purity
≥99%
Appearance
白色至类白色粉末
Packaging
100 mg/vial, 500 mg/vial, customizable upon request
Storage
Powder: -20°C, dry and sealed

Description

Zenagamtide sodium (Amycretin sodium; NN 9487) is a 68-amino-acid single-molecule triple agonist of the GLP-1 receptor (GLP-1R), amylin receptors (AMY1–3) and calcitonin receptor (CTR), developed by Novo Nordisk. It is orally available and brain-penetrant. It is currently in Phase III and not approved anywhere. Manufactured in-house by Ningxia LabsChem. For research use only (RUO); not for human use. Patents remain the property of their respective holders; no patent license is granted.

Usage

For research and industrial development only; not for human or veterinary diagnostic, therapeutic or preventive use. Investigational triple GLP-1/amylin/calcitonin receptor agonist for type 2 diabetes and obesity; oral or subcutaneous administration.

Molecular Sequence

His-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Glu-Gln-Ala-Ala-Arg-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-{C18 diacid-γ-Glu-(AEEA)2-Lys}-Gly-Gly-Gly-Gly-Glu-Ala-Ser-Glu-Leu-Ser-Thr-Ala-Ala-Leu-Gly-Arg-Leu-Ser-Ala-Glu-Leu-His-Glu-Leu-Ala-Thr-Leu-Pro-Arg-Thr-Glu-Thr-Gly-Ser-Gly-Ser-Pro-NH2 (C-terminal prolinamide)

Related Products